Ignite Creation Date:
2025-12-24 @ 2:56 PM
Ignite Modification Date:
2025-12-26 @ 9:13 PM
Study NCT ID:
NCT04893759
Status:
TERMINATED
Last Update Posted:
2025-04-17
First Post:
2021-05-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors
Sponsor:
Ascentage Pharma Group Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-01-06
Start Date Type:
ACTUAL
Primary Completion Date:
2022-09-14
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-09-14
Completion Date Type:
ACTUAL
First Submit Date:
2021-05-11
First Submit QC Date:
None
Study First Post Date:
2021-05-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-15
Last Update Post Date:
2025-04-17
Last Update Post Date Type:
ACTUAL